SEC Form 4 · accession 0000899243-18-008244
EyePoint, Inc. · EYPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nancy Lurker
Officer — President & CEO · Director
Period of report
Mar 19, 2018
Accepted (ET)
Mar 21, 2018 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Mar 19, 2018 | A | 38,333 | $0.00 | A | 95,033 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 19,166 shares representing a previously granted performance stock unit award vested on that date. An additional 19,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.